TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: >1.00E+3nMAssay Description:Inhibition of BACE1More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 3.90nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of BACE1 assessed as amyloid beta (1-40) productionMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
Affinity DataIC50: 8.80nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Binding affinity of the compound towards human neuropeptide Y receptor type 5 in HEK 293 cell line by using [125I]-PYY as radioligandMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Binding affinity of the compound towards human neuropeptide Y receptor type 5 in HEK 293 cell line by using [125I]-PYY as radioligandMore data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of BACE1 assessed as amyloid beta (1-40) productionMore data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of BACE1 assessed as amyloid beta (1-40) productionMore data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of BACE1 assessed as amyloid beta (1-40) productionMore data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
Affinity DataIC50: 36nMAssay Description:Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetBeta-secretase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 36nMAssay Description:Inhibition of BACE1 assessed as amyloid beta (1-40) productionMore data for this Ligand-Target Pair
Affinity DataIC50: 37nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibition of [125I]-PYY binding to recombinant NPY Y5 receptor on HEK-293 cell membranes.More data for this Ligand-Target Pair
Affinity DataIC50: 41nMAssay Description:Displacement of [125I]-Tyr14-nociceptin from human ORL1 expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair
Affinity DataIC50: 47nMAssay Description:Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation countingMore data for this Ligand-Target Pair